High-throughput approaches for precision medicine in high-grade serous ovarian cancer

High-grade serous carcinoma (HGSC) is the most prevalent and aggressive subtype of ovarian cancer. The large degree of clinical heterogeneity within HGSC has justified deviations from the traditional one-size-fits-all clinical management approach. However, the majority of HGSC patients still relapse with chemo-resistant cancer and eventually succumb to their disease, evidence that further work is needed to improve patient outcomes. Advancements in high-throughput technologies have enabled novel insights into biological complexity, offering a large potential for informing precision medicine efforts. Here, we review the current landscape of clinical management for HGSC and highlight applications of high-throughput biological approaches for molecular subtyping and the discovery of putative blood-based biomarkers and novel therapeutic targets. Additionally, we present recent improvements in model systems and discuss how their intersection with high-throughput platforms and technological advancements is positioned to accelerate the realization of precision medicine in HGSC.

• Publication year

  2020

• Venue

  Journal of Hematology & Oncology

• Publication date

  2020-10-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s13045-020-00971-6PMID 33036656PMCID 7547483
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer

  2020cited by this paper
• A single-cell landscape of high-grade serous ovarian cancer

  2020cited by this paper
• Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma

  2020cited by this paper
• Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases

  2020cited by this paper
• Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21

  2020cited by this paper
• Cancer statistics, 2020

  2020cited by this paper
• Hydro-Seq enables contamination-free high-throughput single-cell RNA-sequencing for circulating tumor cells

  2019cited by this paper
• Light-induced structural changes in a full-length cyanobacterial phytochrome probed by time-resolved X-ray scattering

  2019cited by this paper
• Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised placebo‐controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

  2019cited by this paper
• Ovarian Cancer Immunotherapy: Turning up the Heat

  2019cited by this paper
• Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.

  2019cited by this paper
• Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity

  2019cited by this paper
• The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells

  2019cited by this paper
• Epithelial ovarian cancer: Evolution of management in the era of precision medicine

  2019cited by this paper
• Biophysical Principles of Ion-Channel-Mediated Mechanosensory Transduction.

  2019cited by this paper
• The proteomic comparison of peripheral circulation-derived exosomes from the epithelial ovarian carcinoma (EOC) patients and non-EOC subjects

  2019cited by this paper
• Extensive Intratumor Proteogenomic Heterogeneity Revealed by Multiregion Sampling in a High-Grade Serous Ovarian Tumor Specimen

  2019cited by this paper
• Role of human epididymis protein 4 (HE4) in detecting recurrence in CA125 negative ovarian cancer patients

  2019cited by this paper
• Mass Spectrometry-Based Plasma Proteomics: Considerations from Sample Collection to Achieving Translational Data

  2019cited by this paper
• Proteomics reveals NNMT as a master metabolic regulator of cancer associated fibroblasts

  2019cited by this paper
• N-Glycoproteomics of Patient-Derived Xenografts: A Strategy to Discover Tumor-Associated Proteins in High-Grade Serous Ovarian Cancer.

  2019cited by this paper
• Evaluation of Dunphy et al.: Suggestions to Solidify, Clarify, and Focus without Substantial New Work.

  2019cited by this paper
• SurfaceGenie: A web-based application for prioritizing cell-type specific marker candidates

  2019cited by this paper
• Abstract 4709: Extensive intratumor proteogenomic heterogeneity revealed by multiregion sampling in a high-grade serous ovarian tumor specimen

  2019cited by this paper
• Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

  2019cited by this paper
• Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis

  2019cited by this paper
• Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

  2019cited by this paper
• Mesothelial Cell HIF1α Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk.

  2019cited by this paper
• Stochastic simulations reveal few green wave surfing populations among spring migrating herbivorous waterfowl

  2019cited by this paper
• An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity

  2019cited by this paper
• Epithelial ovarian cancer.

  2019cited by this paper
• Light-induced structural changes in a full-length cyanobacterial phytochrome probed by time-resolved X-ray scattering

  2019cited by this paper
• Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

  2019cited by this paper
• Double-slit photoelectron interference in strong-field ionization of the neon dimer

  2018cited by this paper
• Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer.

  2018cited by this paper
• Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types

  2018cited by this paper
• Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.

  2018cited by this paper
• Detection and localization of surgically resectable cancers with a multi-analyte blood test

  2018cited by this paper
• Ovarian Cancer Prevention and Screening.

  2018cited by this paper
• Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma

  2018cited by this paper
• Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins

  2018cited by this paper
• Cancer statistics, 2018

  2018cited by this paper
• Ovarian cancer statistics, 2018

  2018cited by this paper
• Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

  2018cited by this paper
• Sensitive tumour detection and classification using plasma cell-free DNA methylomes

  2018cited by this paper
• Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13

  2018cited by this paper
• Profiling circulating tumour cells and other biomarkers of invasive cancers

  2018cited by this paper
• FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.

  2018cited by this paper
• Analysis of Circulating Tumor Cells in Ovarian Cancer and Their Clinical Value as a Biomarker

  2018cited by this paper
• Extracellular vesicle-associated miRNAs in ovarian cancer – design of an integrated NGS-based workflow for the identification of blood-based biomarkers for platinum-resistance

  2018cited by this paper
• Proteome Profiling of 1 to 5 Spiked Circulating Tumor Cells Isolated from Whole Blood Using Immunodensity Enrichment, Laser Capture Microdissection, Nanodroplet Sample Processing, and Ultrasensitive nanoLC-MS.

  2018cited by this paper
• Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts.

  2017cited by this paper
• Embedded Spheroids as Models of the Cancer Microenvironment

  2017cited by this paper
• Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer.

  2017cited by this paper
• ‘High‐grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease’

  2017cited by this paper
• Liquid biopsies come of age: towards implementation of circulating tumour DNA

  2017cited by this paper
• Copy-number signatures and mutational processes in ovarian carcinoma

  2017cited by this paper
• Erratum to: Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors

  2017cited by this paper
• Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.

  2017cited by this paper
• Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

  2017cited by this paper
• High grade serous ovarian carcinomas originate in the fallopian tube

  2017cited by this paper
• Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.

  2017cited by this paper
• The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer

  2017cited by this paper
• Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2017cited by this paper
• High‐grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease

  2017cited by this paper
• Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

  2017cited by this paper
• Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer.

  2017cited by this paper
• Metas-Chip precisely identifies presence of micrometastasis in live biopsy samples by label free approach

  2017cited by this paper
• Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial.

  2016cited by this paper
• Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

  2016cited by this paper
• Quantification of Somatic Chromosomal Rearrangements in Circulating Cell-Free DNA from Ovarian Cancers

  2016cited by this paper
• Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer.

  2016cited by this paper
• Abstract 440: Quantification of somatic chromosomal rearrangements in circulating cell-free DNA from ovarian cancers

  2016cited by this paper
• Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

  2016cited by this paper
• Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial

  2016cited by this paper
• The role of MicroRNAs in human cancer

  2016cited by this paper
• Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors.

  2016cited by this paper
• Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer

  2016cited by this paper
• The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.

  2016cited by this paper
• Biological roles of glycans

  2016cited by this paper
• Antibody-drug conjugates—an emerging class of cancer treatment

  2016cited by this paper
• Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status

  2016cited by this paper
• Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.

  2016cited by this paper
• Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

  2016cited by this paper
• Corrigendum: Geographic population structure analysis of worldwide human populations infers their biogeographical origins

  2016cited by this paper
• Profile of farletuzumab and its potential in the treatment of solid tumors

  2016cited by this paper
• Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.

  2016cited by this paper
• Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study

  2016cited by this paper
• The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients—results from the OVCAD study

  2016cited by this paper
• Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease

  2016cited by this paper
• Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses.

  2016cited by this paper
• Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses?

  2016cited by this paper
• Corrigendum: Pyruvate Dehydrogenase Kinase 4 Promotes Vascular Calcification via SMAD1/5/8 Phosphorylation

  2016cited by this paper
• Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study

  2016cited by this paper
• Beyond genomics: critical evaluation of cell line utility for ovarian cancer research.

  2015cited by this paper
• PARPs and ADP-Ribosylation: 50 Years … and Counting.

  2015cited by this paper
• Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis

  2015cited by this paper
• Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.

  2015cited by this paper
• Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

  2015cited by this paper
• Targeting the folate receptor for the treatment of ovarian cancer

  2015cited by this paper

• The P7 peptide antagonizes bFGF-induced malignant behaviors of ovarian cancer by inhibiting MEK/ERK signaling pathway

  2026cites this paper
• Association of adjuvant chemotherapy regimen with serial CA-125 kinetics (KELIM framework) and progression-free survival after cytoreductive surgery for ovarian cancer: a retrospective cohort study

  2026cites this paper
• Mechanisms of FOXK1-regulated glycolipid metabolism in mediating TOX-induced histone lactylation to promote CD8⁺ T cell exhaustion in high-grade serous ovarian cancer

  2026cites this paper
• Targeting Akt Signaling Pathway in Cancer: Molecular Mechanisms and Advances in Therapeutic Interventions.

  2025cites this paper
• ID8 cells manifest phenotypic plasticity and molecular heterogeneity of high-grade serous ovarian cancer in response to the local tissue niche

  2025cites this paper
• A stage IV high-grade serous ovarian cancer patient carrying ERBB2 amplification and ERBB2 overexpression benefits from late-line pyrotinib treatment: A case report

  2025cites this paper
• Cross modality learning of cell painting and transcriptomics data improves mechanism of action clustering and bioactivity modelling

  2025cites this paper
• Integrative Transcriptomic Meta-Analysis Reveals Risk Signatures and Immune Infiltration Patterns in High-Grade Serous Ovarian Cancer

  2025cites this paper
• Functional heterogeneity and clinical implications of CD4+ T cell subtypes in high-grade serous ovarian carcinoma

  2025cites this paper
• Uncovering key regulatory pathways and prognostic biomarkers in the tumor microenvironment of high-grade serous ovarian cancer through single-cell RNA sequencing and experimental validation

  2025cites this paper
• A boronic acid functionalized fully conjugated covalent organic framework for significantly improved affinity and fluorescence detection for sialic acid

  2025cites this paper
• Epigenetic regulation in oogenesis and fetal development: insights into m6A modifications

  2025cites this paper
• Self-targeted nanosystem for enhanced chemodynamic cancer therapy.

  2025cites this paper
• Establishment and Its Utility of a Patient-Derived Cell Xenografts (PDCX) Model with Cryopreserved Cancer Cells from Human Tumor

  2025cites this paper
• The Evolution of Next-Generation Sequencing Technologies.

  2025cites this paper
• Epigenetic regulation in female reproduction: the impact of m6A on maternal-fetal health

  2025cites this paper
• Distinct origins of high-grade serous ovarian carcinoma: genetic and epigenetic evidence linking ovarian and fallopian tube epithelium to clinical outcomes and early detection

  2025cites this paper
• Transcriptome analysis of orbital tissue in thyroid eye disease uncovers key pathogenic mediators

  2025cites this paper
• Quality of life and survivorship in patients with low-grade ovarian cancer.

  2024cites this paper
• Targeted Mass Spectrometry of Longitudinal Patient Sera Reveals LTBP1 as a Potential Surveillance Biomarker for High-Grade Serous Ovarian Carcinoma

  2024cites this paper
• Current Applications and Challenges of Next-Generation Sequencing in Plasma Circulating Tumour DNA of Ovarian Cancer

  2024influential citation
• The CDK4/6 Inhibitor Palbociclib Induces Cell Senescence of High-grade Serous Ovarian Cancer Through Acetylation of p53

  2024cites this paper
• Macrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in Bioengineered In Vitro Models of Ovarian Cancer

  2024cites this paper
• The development of a novel zeolite-based assay for efficient and deep plasma proteomic profiling

  2024cites this paper
• Understanding the Molecular Landscape of Endometriosis: A Bioinformatics Approach to Uncover Signaling Pathways and Hub Genes

  2024cites this paper
• Global Incidence of Ovarian Cancer According to Histologic Subtype: A Population-Based Cancer Registry Study

  2024cites this paper
• Targeted therapy in high grade serous ovarian Cancer: A literature review

  2024influential citation
• Transformer-based AI technology improves early ovarian cancer diagnosis using cfDNA methylation markers

  2024cites this paper
• The Impact of Liquid Biopsy in Advanced Ovarian Cancer Care

  2024cites this paper
• Transcriptomic era of cancers in females: new epigenetic perspectives and therapeutic prospects.

  2024cites this paper
• Evolving Landscape of Detection and Targeting miRNA/Epigenetics for Therapeutic Strategies in Ovarian Cancer.

  2024cites this paper
• Inhibition of Selenoprotein I promotes ferroptosis and reverses resistance to platinum chemotherapy by impairing Akt phosphorylation in ovarian cancer

  2024cites this paper
• Research On the Identification of Novel Antigens and The Optimization of Therapeutic Strategies in Cancer Immunotherapy Through Single-Cell Sequencing

  2024cites this paper
• Early prediction and risk stratification of ovarian cancer based on clinical data using machine learning approaches

  2024cites this paper
• Early warning and diagnosis of liver cancer based on dynamic network biomarker and deep learning

  2023cites this paper
• FAK inhibitor PF-562271 inhibits the migration and proliferation of high-grade serous ovarian cancer cells through FAK and FAK mediated cell cycle arrest

  2023cites this paper
• The evolution of next-generation sequencing technologies

  2023cites this paper
• A multi-omics approach to understand the influence of polyphenols in ovarian cancer for precision nutrition: a mini-review

  2023cites this paper
• Patient-derived tumor models in cancer research: Evaluation of the oncostatic effects of melatonin.

  2023cites this paper
• CCNB1 is a novel prognostic biomarker and promotes proliferation, migration and invasion in Wilms tumor

  2023cites this paper
• RNA-seq research landscape in Africa: systematic review reveals disparities and opportunities

  2023cites this paper
• EVI2B Is a Prognostic Biomarker and Is Correlated with Monocyte and Macrophage Infiltration in Osteosarcoma Based on an Integrative Analysis

  2023cites this paper
• Iron nitroprusside as a chemodynamic agent and inducer of ferroptosis for ovarian cancer therapy.

  2023cites this paper
• Silver nitroprusside as an efficient chemodynamic therapeutic agent and a peroxynitrite nanogenerator for targeted cancer therapies

  2023cites this paper
• Computable structured aptamer for targeted treatment of ovarian cancer

  2023cites this paper
• The use of transcriptomic data in developing biomarkers in breast cancer

  2023cites this paper
• Gain-of-function p53R175H blocks apoptosis in a precursor model of ovarian high-grade serous carcinoma

  2023cites this paper
• Identification of immune-related hub genes and miRNA-mRNA pairs involved in immune infiltration in human septic cardiomyopathy by bioinformatics analysis

  2022cites this paper
• N6‐methyladenosine (m6A) modification in gynecological malignancies

  2022cites this paper
• Evaluation of serum tRF-23-Q99P9P9NDD as a potential biomarker for the clinical diagnosis of gastric cancer

  2022cites this paper
• The Roles of Drug Metabolism-Related ADH1B in Immune Regulation and Therapeutic Response of Ovarian Cancer

  2022cites this paper
• GRP75-faciliated Mitochondria-associated ER Membrane (MAM) Integrity controls Cisplatin-resistance in Ovarian Cancer Patients

  2022cites this paper
• Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates

  2022cites this paper
• Combined Usage of MDK Inhibitor Augments Interferon-γ Anti-Tumor Activity in the SKOV3 Human Ovarian Cancer Cell Line

  2022cites this paper
• The application of circulating tumor cell and cell-free DNA liquid biopsies in ovarian cancer.

  2022cites this paper
• Differential Diagnosis of Hematologic and Solid Tumors Using Targeted Transcriptome and Artificial Intelligence (AI).

  2022cites this paper
• Transcriptome Profiling of Eutopic and Ectopic Endometrial Stromal Cells in Women with Endometriosis Based on High-Throughput Sequencing

  2022cites this paper
• Proteomics of High-Grade Serous Ovarian Cancer Models Identifies Cancer-Associated Fibroblast Markers Associated with Clinical Outcomes

  2022cites this paper
• Decreased Levels of GSH Are Associated with Platinum Resistance in High-Grade Serous Ovarian Cancer

  2022cites this paper
• Possible Role of Metformin as an Immune Modulator in the Tumor Microenvironment of Ovarian Cancer

  2021cites this paper
• MKNK2 enhances chemoresistance of ovarian cancer by suppressing autophagy via miR-125b.

  2021cites this paper
• Personalized Models of Heterogenous 3D Epithelial Tumor Microenvironments: Ovarian Cancer as a Model.

  2021cites this paper
• Targeting Akt in cancer for precision therapy

  2021cites this paper
• Origins and Pathology of Epithelial Ovarian Cancer: A Brief Overview

  2021cites this paper
• PTH2R is related to cell proliferation and migration in ovarian cancer: a multi-omics analysis of bioinformatics and experiments

  2021cites this paper
• Genome-editing approaches and applications: a brief review on CRISPR technology and its role in cancer

  2021cites this paper
• RNA sequencing: new technologies and applications in cancer research

  2020cites this paper
• World Journal of Clinical Oncology

  year unknowncites this paper